Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study
David T Yeung(Royal Adelaide Hospital), On Behalf of the ALLG(Australasian Leukaemia and Lymphoma Group), Ken‐Soon Tan(Logan Hospital), Susan Branford(South Australia Pathology), Rosemary Harrup(University of Tasmania), Deborah L. White(ANZCHOG), Howard Mutsando(Toowoomba Hospital), Naranie Shanmuganathan(South Australia Pathology), Kate Burbury(The University of Melbourne), David M. Ross(Flinders Medical Centre), Timothy P. Hughes(Royal Adelaide Hospital), Campbell Tiley(Gosford Hospital), Anthony K. Mills(Princess Alexandra Hospital), Jake Shortt(The University of Melbourne), Richard Eek, John Kwan(Westmead Hospital), Ann Solterbeck, David Kipp(Geelong Hospital), Andrew Grigg(The Royal Melbourne Hospital), Ilona Cunningham(The University of Sydney), Philip A. Rowlings(Medical College of Wisconsin), Matthew P.F. Wright(Fiona Stanley Hospital), Nicholas Viiala(Liverpool Hospital)
Cited by 3
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Solid Cancers after Bone Marrow Transplantation
|New England Journal of Medicine|1997|968